Prioritizing mutational profiling for targeted therapy of lung adenocarcinoma

The Lung Cancer Mutation Consortium (LCMC) was launched as a cross-institutional effort to prospectively follow non-small cell lung cancer (NSCLC) patients across sixteen centers in the US, with a focus on genomic mutation profiles, in an effort to improve the selection of effective therapeutic courses (1). Optimization of personalized therapy has been essential in improving patient care, and is currently highly dependent on comprehensive tumor genome analysis and molecular classification. For instance, personalized treatment of melanoma patients harboring the V600E BRAF variant with BRAF inhibitors (e.g., sorafenib) has become standard-of-care. Yet, despite the relevant number of potential targetable alterations in NSCLC, fully translating genomic testing to the clinic heavily rests on characterizing not only driver mutations in each patient but also potential co-occurring somatic pathogenic mutations that may impact therapeutic selection and responses